Korean startup Mediwhale, founded in 2016, is redefining how we detect and prevent cardiovascular disease. Using retinal biomarkers and artificial intelligence, its flagship product, Dr. Noon CVD, can predict an individual’s risk of developing cardiovascular, renal, or metabolic (CVRM) disease — often before any symptoms appear.
In an interview with HealthTechAsia, co-founder and CEO Kevin Taegeun Choi shared how the company’s technology is addressing diagnostic blind spots left by conventional tests — and unveiled plans for an imminent launch in Saudi Arabia.
PREV
There are no previous posts.